FDA Approves First Treatment for Acid Sphingomyelinase Deficiency
FRIDAY, Sept. 2, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved Xenpozyme (olipudase alfa) for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), a rare genetic disease.
ASMD is caused by the lack of an enzyme needed to break down the complex lipid sphingomyelin, which can accumulate in the liver, spleen, lung, and brain. Xenpozyme infusions provide enzyme replacement therapy.
The approval, which received fast-track, breakthrough therapy, orphan drug, and priority review designations, was based on a randomized controlled study of 31 patients in which treatment with Xenpozyme was found to improve lung function and reduce liver and spleen size. In the clinical trial, 75 percent of pediatric patients and half of adult patients experienced adverse reactions, including headaches, nausea, and vomiting, while receiving the Xenpozyme intravenous infusion.
"ASMD has a debilitating effect on people's lives and there is a critical need to increase treatment options for patients who suffer from this rare disease," Christine Nguyen, M.D., from the FDA Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, said in a statement. "The challenges involved with developing treatments for rare diseases are significant and unique. We believe patients who suffer from ASMD, their families, and their physicians will welcome this long-awaited advancement."
Approval of Xenpozyme was granted to Genzyme.
Was this page helpful?
Related Posts
Good Heart Health in Midlife May Protect Against Depressive Symptoms
FRIDAY, Feb. 17, 2023 (HealthDay News) -- Better cardiovascular health in...
Facebook se convirtió en una red de emergencia en los primeros días de la pandemia
LUNES, 4 de octubre de 2021 (HealthDay News) -- En una emergencia de salud, los...
¿Una dieta rica en fibra podría ayudar a mejorar la supervivencia al cáncer?
LUNES, 27 de diciembre de 2021 (HealthDay News) -- Las personas que se someten a...